{"id":1036366,"date":"2012-06-12T15:15:14","date_gmt":"2012-06-12T15:15:14","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/research-and-markets-company-study-of-walvax-biotechnology-co-ltd-2012.php"},"modified":"2024-08-17T15:55:51","modified_gmt":"2024-08-17T19:55:51","slug":"research-and-markets-company-study-of-walvax-biotechnology-co-ltd-2012","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/research-and-markets-company-study-of-walvax-biotechnology-co-ltd-2012.php","title":{"rendered":"Research and Markets: Company Study of Walvax Biotechnology Co, Ltd.,2012"},"content":{"rendered":"<p><p>      DUBLIN--(BUSINESS WIRE)--    <\/p>\n<p>      Research and Markets (<a href=\"http:\/\/www.researchandmarkets.com\/research\/rddx98\/company_study_of_w\" rel=\"nofollow\">http:\/\/www.researchandmarkets.com\/research\/rddx98\/company_study_of_w<\/a>)      has announced the addition of the       \"Company Study of Walvax Biotechnology Co, Ltd.,2012\"      company profile to their offering.    <\/p>\n<p>      Walvax Biotechnology Co, Ltd., founded in      2001, specializes in research & development, production      and marketing of bio-pharmaceutical vaccines. In September      2010, it went public on the Shenzhen's Growth Enterprise      Market (GEM), with the approval of China Securities      Regulatory Commission (CSRC). Walvax Biotechnology employs about      863 people, including 161 for research and development. It has a      new-type vaccine research & development center and pilot      base at Kunming High-tech Industrial Development Zone      (located in Kunming, Yunnan province) as well as vaccine      production bases at Yuxi Hi-Tech & New Industrial      Development Zone (located in Yuxi, Yunnan province) and      Taizhou National Medical Hi-Tech Development Zone (located in      Taizhou, Jiangsu province). In addition, its marketing      network covers 30 provinces or cities and more than 2000      regions or counties throughout China    <\/p>\n<p>      Key Topics Covered:    <\/p>\n<p>      1 Profile    <\/p>\n<p>      2 Operation    <\/p>\n<p>      3 Revenue Structure    <\/p>\n<p>      4 Gross Margin    <\/p>\n<p>      5 Client and Supplier    <\/p>\n<p>      6 R&D and Investment    <\/p>\n<\/p>\n<p>See the article here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/research-markets-company-study-walvax-145000148.html;_ylt=A2KJjan4XNdPrUQA67n_wgt.\" title=\"Research and Markets: Company Study of Walvax Biotechnology Co, Ltd.,2012\" rel=\"noopener\">Research and Markets: Company Study of Walvax Biotechnology Co, Ltd.,2012<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> DUBLIN--(BUSINESS WIRE)-- Research and Markets (<a href=\"http:\/\/www.researchandmarkets.com\/research\/rddx98\/company_study_of_w\" rel=\"nofollow\">http:\/\/www.researchandmarkets.com\/research\/rddx98\/company_study_of_w<\/a>) has announced the addition of the \"Company Study of Walvax Biotechnology Co, Ltd.,2012\" company profile to their offering. Walvax Biotechnology Co, Ltd., founded in 2001, specializes in research &#038; development, production and marketing of bio-pharmaceutical vaccines <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/research-and-markets-company-study-of-walvax-biotechnology-co-ltd-2012.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-1036366","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036366"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1036366"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036366\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1036366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1036366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1036366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}